NEW YORK (GenomeWeb) – Bristol-Myers Squibb has partnered with Enterome to discover and develop microbiome-derived biomarkers, drug targets, and bioactive molecules that may be used in the development of new cancer companion diagnostics and therapeutics, the companies announced today.

As part of the deal, the companies will also try to identify microbiome biomarkers that can be used to improve the clinical outcomes of patients treated with Bristol-Myers Squibb's immuno-oncology drugs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers examine the gap in funding between researchers and research institutions, ScienceInsider reports

By sequencing two ancient dog genomes, researchers from the US and Germany suggest that dogs were domesticated in a single event, the Washington Post reports.

In Genome Research this week: population dynamics of E. coli infection, lncRNA expression changes in macaque aging, and more.

Noninvasive prenatal testing can uncover pregnancies at risk of miscarriage, New Scientist reports.